Efficacy of tocilizumab, a humanized neutralizing antibody against interleukin-6 receptor, in progressive renal injury associated with Castleman's disease

CEN Case Reports
Akito MaeshimaYoshihisa Nojima

Abstract

Castleman's disease is a benign lymphoproliferative disorder in which interleukin-6 (IL-6), a pleiotropic proinflammatory cytokine, is thought to play a pathogenetic role. Presented is the case of a 72-year-old man with Castleman's disease who exhibited progressive renal dysfunction with proteinuria. Renal biopsy revealed mesangial hypercellularity and matrix expansion in most glomeruli and peritubular inflammatory cell infiltration. Immunofluorescence studies showed intense deposition of IgG in a granular pattern along the glomerular basement membrane. Histological features were compatible with membranoproliferative glomerulonephritis accompanied by interstitial inflammatory cell infiltration. Immunohistological analysis showed that IL-6 was abundantly expressed by tubular cells and interstitial macrophages, suggesting involvement of IL-6 in the renal injury. As a result of administration of tocilizumab, a humanized anti-IL-6 receptor antibody, the patient experienced clinical and biochemical improvement of Castleman's disease, including marked reduction of proteinuria and stabilization of renal function. These findings suggest the efficacy of tocilizumab against Castleman's disease and its renal complications.

References

Jan 1, 1991·American Journal of Nephrology·Y TsukamotoY Kobayashi
Aug 1, 1990·The Journal of Clinical Investigation·S J BrandtA W Nienhuis
Aug 1, 1990·Kidney International·C RuefD L Coleman
Oct 1, 1989·Proceedings of the National Academy of Sciences of the United States of America·S SuematsuT Kishimoto
Jan 1, 1994·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·R N BoswellF J van der Woude
Jan 1, 1993·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·M H RaasveldR J ten Berge
Jul 20, 2001·Journal of the American Society of Nephrology : JASN·Akito MaeshimaItaru Kojima
Jul 1, 1956·Cancer·B CASTLEMANV P MENENDEZ
Dec 2, 2004·The Journal of Pharmacology and Experimental Therapeutics·Nimesh S A PatelChristoph Thiemermann
May 31, 2007·Current Opinion in Hematology·Anu Dham, Bruce A Peterson
Mar 14, 2008·Journal of the American Society of Nephrology : JASN·Yael Nechemia-ArbelyJonathan H Axelrod
Jun 20, 2008·The Journal of Surgical Research·Mark LaSpinaDilip S Kittur
Nov 11, 2008·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Sumeet SunejaJoanne M Bargman
Jul 3, 2009·American Journal of Physiology. Renal Physiology·Mari Tomiyama-HanayamaNorihiro Nishimoto
Jul 27, 2010·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Khalil El KarouiEric Daugas
May 24, 2011·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Damin XuHong Zhang

❮ Previous
Next ❯

Citations

Jul 12, 2014·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Simon A JonesGareth W Jones
Apr 28, 2020·CEN Case Reports·Daichi FukayaHirokazu Okada
Sep 23, 2020·Open Biology·Antonella FaraBakri M Assas

❮ Previous
Next ❯

Related Concepts

Related Feeds

Castleman Disease

Castleman disease is a rare disorder that involves an overgrowth of cells in the lymph nodes. Unicentric Castleman disease affects one lymph node, usually in the chest or abdomen. Multicentric Castleman disease affects multiple lymph nodes, commonly located in the neck, collarbone, underarm and groin areas. Discover the latest research on Castleman disease here.